Evoke Pharma receives notice of allowance from USPTO for Gimoti patent

Evoke Pharma (EVOK) announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for a U.S. patent application covering the use of Gimoti in patients with moderate to severe symptoms of gastroparesis. The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke’s intellectual property estate around intranasal metoclopramide. Upon issuance, the patent will be expected to expire in December 2036 and the company intends to list the patent in the FDA’s Orange Book, extending market exclusivity for Gimoti beyond other existing patents.